Kyverna Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-52.4M | $-53.0M | $621.0K | $2.2M |
| FY2024 | $-114.3M | $-116.5M | $2.2M | $8.4M |
| FY2025 | $-153.7M | $-153.7M | $5.0K | $10.1M |
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2023 | $-52.4M | $-53.0M | $621.0K | $2.2M |
| FY2024 | $-114.3M | $-116.5M | $2.2M | $8.4M |
| FY2025 | $-153.7M | $-153.7M | $5.0K | $10.1M |